A doctor makes a diagnosis of insomnia if a patient complains of lack of sleep or its poor quality for a long time. Difficulty falling asleep, frequent waking up in the middle of the night, feeling tired and drowsy during the day – these signs that occur without objective reasons indicate a problem that often
- Posted by: Vascular Pharmaceuticals
- 2020-06-08
Are All Brand Medications Available as Generics?
Almost any expensive medicine has a more affordable analogue. And yet, why such a difference in prices? And is it not dangerous to save on expensive drugs, preferring cheaper ones? In simple terms, the reason is as follows. Someone develops medicine: pharmacologists find a treatment molecule, synthesize a substance, and together with biologists and doctors,
- Posted by: Vascular Pharmaceuticals
- 2020-04-16
The Risks of Misusing Valsartan and Possible Alternatives
What is valsartan? Valsartan, also marketed under the brand name of Diovan, is a powerful anti-hypertonic medication widely used to decrease high blood pressure in chronic hypertensive patients, treat cardiac insufficiency, and reduce the risk of invalidity and death in myocardial infarction survivors. The FDA initially approved this blood pressure-regulating drug for medical use in
- Posted by: Vascular Pharmaceuticals
- 2015-02-03
Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing
Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing Funding to support Phase 2 clinical trial of VPI-2690B for treatment of diabetic nephropathy CHAPEL HILL, NC, March 2, 2015, Vascular Pharmaceuticals, Inc. (VPI), a clinical-stage pharmaceutical company addressing the complications of diabetes, announced today that it has increased its Series A financing with the
- Posted by: Vascular Pharmaceuticals
- 2014-11-14
Vascular Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of VPI-2690B for Diabetic Nephropathy
Chapel Hill, NC, November 13, 2014, Vascular Pharmaceuticals, Inc. announced today that it has initiated a Phase 2 clinical trial of VPI-2690B for the treatment of diabetic nephropathy. VPI-2690B is a first in class monoclonal antibody that binds to a unique molecular target within the αVß3 receptor. VPI-2690B was found to be safe and well tolerated
- Posted by: Vascular Pharmaceuticals
- 2012-09-12
Vascular Pharmaceuticals, Inc. Completes $16 Million Equity Financing, Signs Agreement with Janssen Biotech, Inc
CHAPEL HILL, NC, September 12, 2012, Vascular Pharmaceuticals, Inc. (Vascular Pharma), a drug discovery company developing an innovative product to treat patients with complications arising from diabetes, announced today that it has successfully completed a $16 million Series A equity financing. The Series A financing was co-led by Intersouth Partners and MPM Capital and is the